STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #588 by analyst upside · 2026-06-27
PYXS
Pyxis Oncology, Inc.
Healthcare · Market Cap $175M · P/E 0x
ANALYST PRICE TARGET
+152.7%
implied upside to consensus target
Current Price $2.77
Consensus Target $7.0
Bull Target $9.0
Bear Target $5.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
1
Sell
0
52-Week Low $0.97
52-Week High $5.55
YTD Return +140.9%
FUNDAMENTALS
Market Cap $175M
P/E Ratio (TTM) N/A
Forward P/E -2.2x
EPS (TTM) $-1.30
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $14M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.97
52-Week High $5.55
Current Price $2.77
Bear Target $5.0
Bull Target $9.0
● Now $2.77 ● Target $7.0
TRADING DATA
Avg Volume 523K
YTD Return +140.9%
Analyst Count 8
Consensus Buy
Upside to Target +152.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Pyxis Oncology, Inc. (PYXS) is currently trading at $2.77 with a Wall Street consensus price target of $7.0, implying potential upside of 152.7% over the next 12 months. 8 analysts currently cover PYXS, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $5.0.

PYXS operates in the Healthcare sector with a market capitalisation of $175M. The stock is up 140.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.97 – $5.55.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PYXS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush ● Initiated
Outperform 2026-05-05 Building track record
Stifel — Reiterated
Buy → Buy 2026-03-24 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-24 31% win rate (48 calls)
RBC Capital — Reiterated
Outperform → Outperform 2025-12-19 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-12-19 31% win rate (48 calls)
Stephens & Co. — Reiterated
Overweight → Overweight 2025-11-24 Building track record
Guggenheim — Reiterated
Buy → Buy 2025-11-04 62% win rate (8 calls)
Guggenheim ● Initiated
Buy 2025-09-04 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
17/30
Consensus clarity
1/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →